<DOC>
	<DOCNO>NCT00002279</DOCNO>
	<brief_summary>AMENDED : To provide ddC patient AIDS advance ARC fail treatment , intolerant ineligible receive zidovudine ( AZT ) demonstrate ddC monotherapy safe , tolerable patient population . Original design : To provide zalcitabine ( dideoxycytidine ; ddC ) patient AIDS advance AIDS-related complex ( ARC ) fail treatment intolerant zidovudine ( AZT ) also intolerant dideoxyinosine ( ddI ) ; demonstrate ddC monotherapy safe tolerable treatment patient previously experience either treatment failure , hematologic intolerance myositis AZT treatment pancreatitis toxicity ( except peripheral neuropathy ddI ) .</brief_summary>
	<brief_title>A Study ddC Patients With AIDS Advanced AIDS-Related Complex ( ARC ) Who Have Not Had Success With Zidovudine ( AZT )</brief_title>
	<detailed_description>The first 50 patient enrol study investigator prior ddC experience , specifically AIDS Clinical Trials Group ( ACTG ) , non-ACTG investigator list ddC protocol NIAID ACTG 012 , 112 , 047 , 050 , 106 ( N3447 ) , 114 ( N3300 ) , 119 ( N3492 ) , N3226 , investigator ACTG center ACTG satellite center knowledge ddC therapy . Once 50 patient enter 25 complete four week treatment study dependent upon receipt complete case form week # 4 treatment 25 patient review evaluated safety . Patients 51-200 may enter physician licensed state experience AIDS patient agree follow patient specify protocol . After 200 enter week # 16 case report form return ddC Coordinating Center review safety 100 200 patient , protocol would open without limit number patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : Aerosolized Pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Allowed : Drugs treatment could cause serious additive toxicity coadministered study medication allow treatment acute intercurrent illness opportunistic infection discretion investigator . Isoniazid , evidence peripheral neuropathy entry patient take pyridoxine = &gt; 50 mg/day . Metronidazole , study drug interruption ; neurological exam perform treatment metronidazole ddC restart sign , symptom neurological finding suggestive peripheral neuropathy . It recommend patient require amphotericin , pyrimethamine , sulfadiazine , intravenous trimethoprim / sulfamethoxazole , ganciclovir , intravenous pentamidine , intravenous acyclovir acyclovir = &gt; 1000 mg/day orally bone marrow renal toxic drug interruption ddC stable two week maintenance dose medication ddC restart . Patients amphotericin , pyrimethamine , sulfadiazine , trimethoprim / sulfamethoxazole , ganciclovir , intravenous acyclovir acyclovir = &gt; 1000 mg/day orally bone marrow renal toxic drug may tolerate concomitant ddC . If drug give concomitantly ddC , patient frequent ( weekly ) laboratory assessment , appropriate . Drugs nephrotoxic potential cause peripheral neuropathy might expect cause increase toxicity coadministered ddC . Concurrent Treatment : Allowed : Radiation therapy dideoxycytidine ( ddC ) interruption stable 2 week treatment . AMENDED : Treatment category : AZT treatment failure . AZT intolerance . AZT ineligibility Original design : Patients must diagnosis AIDS AIDSrelated complex ( ARC ) fall one follow 2 category : Zidovudine ( AZT ) treatment failure dideoxyinosine ( ddI ) intolerance AZT intolerance ddI intolerance . Under 18 year age must consent parent guardian . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Any history peripheral neuropathy due cause , even peripheral neuropathy reason discontinuation antiHIV therapy . Any finding suggestive peripheral neuropathy find neurological exam . If patient isolate finding absent achilles reflex may enter sign symptoms finding suggestive peripheral neuropathy . Neoplasms Kaposi 's sarcoma basal cell carcinoma . Concurrent Medication : Excluded : Other experimental drug . Other retroviral nucleoside analog . Immunomodulators Systemic corticosteroid . Drugs known nephrotoxic hepatotoxic potential . Drugs likely cause peripheral neuropathy . Avoid due potential cause peripheral neuropathy : Chloramphenicol . Iodoquinol . Phenytoin . Ethionamide . Gold . Ribavirin . Vincristine . Cisplatin . Dapsone . Disulfiram . Glutethimide . Hydralazine . Nitrofurantoin . Patients follow excluded : Any history peripheral neuropathy due cause . Any finding suggestive peripheral neuropathy find baseline neurological exam . Neoplasms Kaposi 's sarcoma basal cell carcinoma . Unwillingness deem unable sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1991</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>